21:10 , May 9, 2019 |  BioCentury  |  Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
21:34 , May 8, 2019 |  BC Extra  |  Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

Viva will begin trading Thursday after raising HK$1.5 billion (US$193.9 million) early Wednesday in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech Holdings (HKSE:1873) sold 345 million...
20:07 , Apr 26, 2019 |  BC Week In Review  |  Financial News

CRO Viva could get $749M valuation in Hong Kong listing, Ascentage refiles

Viva would raise HK$1.4 billion ($172.2 million) and be valued at HK$5.9 billion ($748.7 million) if the drug discovery services company prices its Hong Kong IPO at the midpoint of the range it proposed April...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
18:17 , Jul 27, 2018 |  BC Week In Review  |  Financial News

CRO Viva Biotech proposes HKEX listing

Viva Biotech Holdings (Shanghai, China) proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX). In addition to the traditional cash-for-service model, the CRO plans to incubate 12 early stage R&D projects per year...
20:39 , Jul 7, 2017 |  BC Week In Review  |  Company News

Fidelity filings show cut to Moderna's valuation

A comparison of regulatory filings showed Fidelity slashed its valuation of Moderna Therapeutics Inc. (Cambridge, Mass.) by 34%. A filing issued June 28 said Fidelity valued Moderna at $5.80 per share as of April 30,...
23:53 , Jun 29, 2017 |  BC Extra  |  Financial News

Fidelity filings show cut to Moderna's valuation

A comparison of regulatory filings showed Fidelity slashed its valuation of Moderna Therapeutics Inc. (Cambridge, Mass.) by 34%. A filing issued Wednesday said Fidelity valued Moderna at $5.80 per share as of April 30, down...
07:00 , Sep 12, 2016 |  BioCentury  |  Finance

Back for more

Less than a year after big funds including Fidelity slashed their valuations of Moderna Therapeutics Inc. , the firms are buying more of the mRNA therapeutics developer in a stepped-up round. Last week, Moderna raised...
07:00 , Sep 14, 2015 |  BioCentury  |  Finance

Gaining leverage

Carl Icahn wants to buy up convertible notes of Vivus Inc. (NASDAQ:VVUS), and if the debt holders agree to his terms the financier would gain a major bargaining chip with the obesity play. Vivus shareholders...